SEC Form 4/A · accession 0001859453-26-000013

Vera Therapeutics, Inc. · VERA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

This is an amendment (Form 4/A). It replaces an earlier filing for the same period.

Reporting owner

Marshall Fordyce

Officer — PRESIDENT AND CEO · Director

Period of report

Jul 7, 2026

Accepted (ET)

Aug 12, 2026 · 6:42 pm EDT

Rule 10b5-1 plan

yes — trade under a plan

Issuer CIK

0001831828

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Class A Common Stock^F1	Jul 7, 2026	M	46,250	$2.8968	A	281,494	D
Class A Common Stock^F3,F1	Jul 7, 2026	S	1,000	$40.7762	D	280,494	D
Class A Common Stock^F4,F1	Jul 7, 2026	S	32,550	$42.0736	D	247,944	D
Class A Common Stock^F5,F1	Jul 7, 2026	S	10,500	$42.8578	D	237,444	D
Class A Common Stock^F6,F1	Jul 7, 2026	S	2,200	$43.5947	D	235,244	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F7	$2.8968	Jul 7, 2026	M	46,250	D	—	Dec 15, 2030	Class A Common Stock	46,250	525,801	D

Explanation of responses

F1This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)".
F2The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
F3The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.39 to $41.31, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F4The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.40 to $42.39, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F5The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.40 to $43.38, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F6The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.42 to $43.97, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F71/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter.